| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonoscopy | 16 | 2022 | 60 | 4.400 |
Why?
|
| Endoscopes, Gastrointestinal | 19 | 2010 | 19 | 3.010 |
Why?
|
| Endoscopy, Gastrointestinal | 16 | 2013 | 29 | 2.330 |
Why?
|
| Medical Records Systems, Computerized | 12 | 2015 | 21 | 1.970 |
Why?
|
| Humans | 140 | 2022 | 28912 | 1.460 |
Why?
|
| Pancreatic Neoplasms | 9 | 2019 | 548 | 1.320 |
Why?
|
| Colorectal Neoplasms | 6 | 2018 | 142 | 1.290 |
Why?
|
| Endosonography | 10 | 2012 | 37 | 1.260 |
Why?
|
| Middle Aged | 57 | 2022 | 7420 | 1.260 |
Why?
|
| Gastrointestinal Diseases | 8 | 2020 | 55 | 1.230 |
Why?
|
| Aged | 49 | 2020 | 5604 | 1.120 |
Why?
|
| Primary Health Care | 6 | 2015 | 161 | 1.110 |
Why?
|
| Male | 68 | 2022 | 13947 | 1.080 |
Why?
|
| Female | 66 | 2022 | 15651 | 1.020 |
Why?
|
| Electronic Health Records | 4 | 2016 | 65 | 0.980 |
Why?
|
| Mass Screening | 4 | 2015 | 158 | 0.890 |
Why?
|
| Capsule Endoscopy | 3 | 2015 | 7 | 0.850 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 6 | 2010 | 19 | 0.820 |
Why?
|
| Endoscopy, Digestive System | 4 | 2016 | 19 | 0.790 |
Why?
|
| Reminder Systems | 5 | 2011 | 11 | 0.790 |
Why?
|
| HIV Infections | 4 | 2011 | 165 | 0.780 |
Why?
|
| Colonic Polyps | 5 | 2018 | 17 | 0.750 |
Why?
|
| Internal Medicine | 7 | 2009 | 28 | 0.740 |
Why?
|
| Veterans | 2 | 2022 | 69 | 0.740 |
Why?
|
| Cecum | 1 | 2022 | 14 | 0.730 |
Why?
|
| Health Resources | 4 | 2017 | 19 | 0.730 |
Why?
|
| Adult | 36 | 2020 | 8038 | 0.660 |
Why?
|
| Adenoma | 4 | 2018 | 61 | 0.650 |
Why?
|
| Treatment Outcome | 17 | 2019 | 2426 | 0.640 |
Why?
|
| Pancreatitis | 2 | 2019 | 36 | 0.630 |
Why?
|
| Video Recording | 2 | 2011 | 41 | 0.630 |
Why?
|
| Catheterization | 2 | 2010 | 50 | 0.620 |
Why?
|
| Information Dissemination | 3 | 2015 | 37 | 0.620 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2019 | 26 | 0.620 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 6 | 0.610 |
Why?
|
| Equipment Design | 17 | 2010 | 218 | 0.610 |
Why?
|
| Technology Assessment, Biomedical | 7 | 2010 | 9 | 0.610 |
Why?
|
| Free Tissue Flaps | 1 | 2019 | 5 | 0.610 |
Why?
|
| Endoscopes | 2 | 2010 | 7 | 0.610 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 29 | 0.610 |
Why?
|
| Spinal Neoplasms | 1 | 2019 | 40 | 0.610 |
Why?
|
| Diphenhydramine | 2 | 2018 | 3 | 0.600 |
Why?
|
| Digestive System Diseases | 2 | 2011 | 3 | 0.600 |
Why?
|
| Endoscopy | 2 | 2010 | 57 | 0.590 |
Why?
|
| Hypnotics and Sedatives | 2 | 2018 | 29 | 0.590 |
Why?
|
| Rural Health Services | 2 | 2010 | 25 | 0.580 |
Why?
|
| United States | 18 | 2019 | 2227 | 0.570 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2019 | 72 | 0.570 |
Why?
|
| Anti-Retroviral Agents | 2 | 2010 | 16 | 0.570 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2019 | 481 | 0.570 |
Why?
|
| Deep Sedation | 1 | 2018 | 1 | 0.570 |
Why?
|
| Guideline Adherence | 4 | 2011 | 95 | 0.560 |
Why?
|
| Patient Satisfaction | 8 | 2005 | 96 | 0.560 |
Why?
|
| Adenocarcinoma | 4 | 2014 | 300 | 0.550 |
Why?
|
| Patient Preference | 2 | 2015 | 34 | 0.550 |
Why?
|
| Indiana | 11 | 2015 | 13 | 0.530 |
Why?
|
| Evidence-Based Medicine | 5 | 2010 | 146 | 0.530 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2011 | 167 | 0.530 |
Why?
|
| Cost Savings | 2 | 2016 | 19 | 0.530 |
Why?
|
| Decision Support Systems, Clinical | 3 | 2011 | 10 | 0.520 |
Why?
|
| Physicians, Family | 4 | 2001 | 13 | 0.520 |
Why?
|
| Asthma | 3 | 2005 | 61 | 0.520 |
Why?
|
| Minimally Invasive Surgical Procedures | 4 | 2010 | 81 | 0.510 |
Why?
|
| Pancreatic Diseases | 4 | 2009 | 13 | 0.510 |
Why?
|
| Enteral Nutrition | 4 | 2011 | 23 | 0.510 |
Why?
|
| Gastroenterologists | 1 | 2016 | 6 | 0.500 |
Why?
|
| Equipment and Supplies | 1 | 2016 | 12 | 0.500 |
Why?
|
| Carcinoma, Papillary | 2 | 2006 | 18 | 0.500 |
Why?
|
| Curriculum | 4 | 2013 | 304 | 0.500 |
Why?
|
| Heart Failure | 5 | 2007 | 253 | 0.490 |
Why?
|
| Device Approval | 3 | 2011 | 6 | 0.490 |
Why?
|
| Quality of Health Care | 3 | 2003 | 83 | 0.490 |
Why?
|
| Intestinal Polyps | 2 | 2015 | 5 | 0.480 |
Why?
|
| Thyroid Neoplasms | 2 | 2006 | 39 | 0.480 |
Why?
|
| United States Food and Drug Administration | 3 | 2011 | 46 | 0.480 |
Why?
|
| Retrospective Studies | 17 | 2020 | 2638 | 0.480 |
Why?
|
| Access to Information | 2 | 2015 | 8 | 0.470 |
Why?
|
| Medical Informatics | 1 | 2016 | 13 | 0.470 |
Why?
|
| Safety Management | 3 | 2010 | 13 | 0.470 |
Why?
|
| Proton Pump Inhibitors | 2 | 2020 | 27 | 0.470 |
Why?
|
| Outpatient Clinics, Hospital | 3 | 2006 | 7 | 0.470 |
Why?
|
| Adenomatous Polyps | 1 | 2015 | 1 | 0.460 |
Why?
|
| Rectal Diseases | 1 | 2015 | 10 | 0.460 |
Why?
|
| Conscious Sedation | 2 | 2015 | 10 | 0.450 |
Why?
|
| Cohort Studies | 9 | 2016 | 898 | 0.440 |
Why?
|
| Family Practice | 3 | 2004 | 45 | 0.440 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2005 | 68 | 0.440 |
Why?
|
| Advance Directives | 3 | 2001 | 13 | 0.440 |
Why?
|
| Postoperative Complications | 1 | 2019 | 634 | 0.440 |
Why?
|
| Stents | 4 | 2009 | 121 | 0.430 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2009 | 45 | 0.420 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2014 | 12 | 0.420 |
Why?
|
| Neoplasm Staging | 4 | 2006 | 480 | 0.420 |
Why?
|
| Cathartics | 2 | 2015 | 11 | 0.420 |
Why?
|
| Prospective Studies | 11 | 2015 | 1280 | 0.420 |
Why?
|
| Preoperative Care | 3 | 2015 | 81 | 0.410 |
Why?
|
| Medical Laboratory Science | 2 | 2010 | 5 | 0.400 |
Why?
|
| Feces | 1 | 2014 | 117 | 0.400 |
Why?
|
| Equipment Safety | 9 | 2010 | 19 | 0.390 |
Why?
|
| Gastroscopy | 2 | 2011 | 7 | 0.390 |
Why?
|
| Image Enhancement | 2 | 2014 | 59 | 0.380 |
Why?
|
| Surgical Instruments | 2 | 2009 | 15 | 0.380 |
Why?
|
| Gastric Mucosa | 2 | 2012 | 35 | 0.380 |
Why?
|
| Health Status | 2 | 2007 | 149 | 0.380 |
Why?
|
| Microbiota | 1 | 2014 | 98 | 0.370 |
Why?
|
| Myocardial Infarction | 2 | 2005 | 351 | 0.370 |
Why?
|
| Aged, 80 and over | 17 | 2020 | 2065 | 0.370 |
Why?
|
| Internship and Residency | 4 | 2009 | 250 | 0.370 |
Why?
|
| Medical Informatics Applications | 2 | 2006 | 7 | 0.360 |
Why?
|
| Intestinal Mucosa | 3 | 2012 | 198 | 0.360 |
Why?
|
| Lung Diseases, Obstructive | 3 | 2001 | 16 | 0.350 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2011 | 11 | 0.340 |
Why?
|
| Sphincterotomy, Endoscopic | 2 | 2010 | 3 | 0.340 |
Why?
|
| Propofol | 1 | 2011 | 10 | 0.340 |
Why?
|
| Chronic Disease | 4 | 2003 | 274 | 0.340 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2008 | 41 | 0.330 |
Why?
|
| Drug Monitoring | 1 | 2011 | 36 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 3 | 2004 | 245 | 0.330 |
Why?
|
| Tattooing | 1 | 2010 | 6 | 0.330 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 70 | 0.330 |
Why?
|
| Radioactive Hazard Release | 1 | 2010 | 1 | 0.330 |
Why?
|
| Ergonomics | 1 | 2010 | 2 | 0.330 |
Why?
|
| Jejunostomy | 1 | 2010 | 5 | 0.330 |
Why?
|
| Protective Devices | 1 | 2010 | 5 | 0.330 |
Why?
|
| Recurrence | 4 | 2019 | 327 | 0.320 |
Why?
|
| Anti-Ulcer Agents | 2 | 2009 | 14 | 0.320 |
Why?
|
| Time Factors | 6 | 2018 | 1615 | 0.320 |
Why?
|
| Surveys and Questionnaires | 12 | 2011 | 1002 | 0.320 |
Why?
|
| Occupational Exposure | 1 | 2010 | 28 | 0.320 |
Why?
|
| Calculi | 1 | 2009 | 1 | 0.310 |
Why?
|
| Gallstones | 1 | 2009 | 9 | 0.310 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 93 | 0.310 |
Why?
|
| Risk Assessment | 6 | 2019 | 631 | 0.310 |
Why?
|
| Colonic Neoplasms | 4 | 2014 | 122 | 0.300 |
Why?
|
| Hemostasis, Surgical | 1 | 2009 | 7 | 0.300 |
Why?
|
| Microscopy | 1 | 2009 | 38 | 0.300 |
Why?
|
| Decision Making, Computer-Assisted | 2 | 2001 | 5 | 0.300 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2009 | 1 | 0.300 |
Why?
|
| Respiratory Tract Fistula | 1 | 2009 | 2 | 0.300 |
Why?
|
| Pleural Diseases | 1 | 2009 | 3 | 0.300 |
Why?
|
| Microscopy, Confocal | 1 | 2009 | 113 | 0.300 |
Why?
|
| Pancreatitis, Chronic | 1 | 2009 | 7 | 0.300 |
Why?
|
| Patient Admission | 2 | 2005 | 30 | 0.300 |
Why?
|
| Pancreatic Fistula | 1 | 2009 | 14 | 0.300 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2011 | 13 | 0.290 |
Why?
|
| Gastroesophageal Reflux | 1 | 2009 | 84 | 0.290 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 236 | 0.280 |
Why?
|
| Sensitivity and Specificity | 9 | 2014 | 524 | 0.280 |
Why?
|
| Health Services Accessibility | 2 | 2007 | 121 | 0.280 |
Why?
|
| Decision Making | 3 | 2003 | 179 | 0.280 |
Why?
|
| Physician-Patient Relations | 5 | 2003 | 116 | 0.270 |
Why?
|
| Lamivudine | 1 | 2007 | 2 | 0.270 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2007 | 8 | 0.270 |
Why?
|
| Hepatitis B | 1 | 2007 | 13 | 0.270 |
Why?
|
| Coronary Disease | 2 | 2005 | 120 | 0.270 |
Why?
|
| Health Care Costs | 2 | 1997 | 50 | 0.260 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2019 | 12 | 0.260 |
Why?
|
| Anesthetics, Intravenous | 2 | 2018 | 15 | 0.250 |
Why?
|
| Utilization Review | 1 | 2006 | 9 | 0.250 |
Why?
|
| Urban Health Services | 1 | 2006 | 9 | 0.250 |
Why?
|
| Public Health Administration | 1 | 2006 | 15 | 0.250 |
Why?
|
| Hospitals, Teaching | 1 | 2006 | 26 | 0.250 |
Why?
|
| Age Factors | 9 | 2010 | 737 | 0.240 |
Why?
|
| Current Procedural Terminology | 4 | 2010 | 11 | 0.240 |
Why?
|
| Quality of Life | 8 | 2007 | 521 | 0.240 |
Why?
|
| Health Plan Implementation | 1 | 2006 | 9 | 0.240 |
Why?
|
| Research | 3 | 2020 | 93 | 0.240 |
Why?
|
| Controlled Clinical Trials as Topic | 3 | 2010 | 4 | 0.230 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2005 | 5 | 0.230 |
Why?
|
| Analgesics, Opioid | 2 | 2018 | 121 | 0.230 |
Why?
|
| United States Department of Veterans Affairs | 4 | 2007 | 26 | 0.230 |
Why?
|
| Abdominal Pain | 2 | 2019 | 35 | 0.230 |
Why?
|
| Referral and Consultation | 3 | 2022 | 98 | 0.230 |
Why?
|
| Follow-Up Studies | 9 | 2009 | 1032 | 0.230 |
Why?
|
| Gastroenterology | 2 | 2018 | 15 | 0.230 |
Why?
|
| Incidence | 3 | 2019 | 572 | 0.230 |
Why?
|
| Professional-Patient Relations | 2 | 2015 | 28 | 0.220 |
Why?
|
| Adolescent | 8 | 2020 | 3199 | 0.220 |
Why?
|
| Diabetes Complications | 1 | 2005 | 66 | 0.220 |
Why?
|
| Risk Factors | 8 | 2010 | 2129 | 0.220 |
Why?
|
| Health Status Indicators | 3 | 2007 | 25 | 0.220 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 64 | 0.220 |
Why?
|
| Patient Access to Records | 2 | 2015 | 2 | 0.220 |
Why?
|
| Reproducibility of Results | 7 | 2014 | 787 | 0.220 |
Why?
|
| Physicians | 3 | 2011 | 83 | 0.220 |
Why?
|
| Kidney Failure, Chronic | 2 | 1998 | 70 | 0.210 |
Why?
|
| Papanicolaou Test | 2 | 1995 | 25 | 0.210 |
Why?
|
| Vaginal Smears | 2 | 1995 | 45 | 0.210 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2004 | 5 | 0.210 |
Why?
|
| Pharmacists | 2 | 2002 | 74 | 0.210 |
Why?
|
| Biomedical Research | 2 | 2020 | 98 | 0.210 |
Why?
|
| African Americans | 3 | 2007 | 352 | 0.210 |
Why?
|
| Midazolam | 3 | 2018 | 8 | 0.200 |
Why?
|
| Stroke | 1 | 2007 | 261 | 0.200 |
Why?
|
| Internal-External Control | 1 | 2003 | 17 | 0.200 |
Why?
|
| Young Adult | 5 | 2020 | 2841 | 0.200 |
Why?
|
| Costs and Cost Analysis | 4 | 2016 | 40 | 0.200 |
Why?
|
| Fentanyl | 3 | 2018 | 35 | 0.200 |
Why?
|
| Mass Media | 1 | 2003 | 9 | 0.200 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 215 | 0.200 |
Why?
|
| Calcium Channel Blockers | 1 | 2003 | 41 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2014 | 409 | 0.190 |
Why?
|
| Antihypertensive Agents | 1 | 2003 | 56 | 0.190 |
Why?
|
| Patient Compliance | 4 | 2010 | 76 | 0.190 |
Why?
|
| Benchmarking | 2 | 2022 | 33 | 0.190 |
Why?
|
| Needles | 3 | 2013 | 26 | 0.190 |
Why?
|
| Pharmacies | 1 | 2002 | 19 | 0.190 |
Why?
|
| Forecasting | 2 | 2019 | 76 | 0.180 |
Why?
|
| Biopsy | 3 | 2019 | 208 | 0.180 |
Why?
|
| Patient Education as Topic | 2 | 2001 | 91 | 0.180 |
Why?
|
| Depression | 2 | 1996 | 225 | 0.180 |
Why?
|
| Health Behavior | 1 | 2003 | 159 | 0.180 |
Why?
|
| Education, Pharmacy, Continuing | 1 | 2001 | 2 | 0.170 |
Why?
|
| Vascular Neoplasms | 1 | 2001 | 3 | 0.170 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2001 | 5 | 0.170 |
Why?
|
| Ampulla of Vater | 1 | 2001 | 6 | 0.170 |
Why?
|
| Community Pharmacy Services | 1 | 2001 | 22 | 0.170 |
Why?
|
| Histamine H2 Antagonists | 1 | 2020 | 7 | 0.170 |
Why?
|
| Myocardial Ischemia | 2 | 1998 | 73 | 0.170 |
Why?
|
| Esophageal Neoplasms | 2 | 2014 | 33 | 0.170 |
Why?
|
| Terminal Care | 2 | 2001 | 43 | 0.170 |
Why?
|
| Models, Statistical | 2 | 2001 | 128 | 0.170 |
Why?
|
| Sex Factors | 4 | 2011 | 469 | 0.160 |
Why?
|
| Length of Stay | 3 | 2019 | 245 | 0.160 |
Why?
|
| Fellowships and Scholarships | 2 | 2018 | 40 | 0.160 |
Why?
|
| Intestine, Small | 2 | 2013 | 66 | 0.160 |
Why?
|
| Pancreas | 2 | 2019 | 63 | 0.160 |
Why?
|
| ROC Curve | 2 | 2019 | 144 | 0.160 |
Why?
|
| Transportation of Patients | 1 | 2000 | 29 | 0.160 |
Why?
|
| Disinfection | 2 | 2010 | 10 | 0.160 |
Why?
|
| Ultrasonography, Interventional | 2 | 2012 | 40 | 0.160 |
Why?
|
| Injections, Spinal | 1 | 2019 | 7 | 0.160 |
Why?
|
| Medicaid | 1 | 2000 | 55 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 8 | 2005 | 115 | 0.150 |
Why?
|
| Hospitals, Urban | 2 | 2004 | 7 | 0.150 |
Why?
|
| Health Policy | 1 | 2000 | 61 | 0.150 |
Why?
|
| Logistic Models | 5 | 1998 | 410 | 0.150 |
Why?
|
| Disease Management | 1 | 2020 | 91 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 53 | 0.150 |
Why?
|
| Attitude to Health | 2 | 2000 | 89 | 0.150 |
Why?
|
| Case Management | 1 | 1998 | 11 | 0.150 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 100 | 0.150 |
Why?
|
| Nephrology | 1 | 1998 | 5 | 0.150 |
Why?
|
| Self-Assessment | 1 | 1998 | 10 | 0.150 |
Why?
|
| Confidentiality | 2 | 2016 | 10 | 0.150 |
Why?
|
| Kenya | 3 | 2011 | 34 | 0.140 |
Why?
|
| Pain, Procedural | 1 | 2018 | 1 | 0.140 |
Why?
|
| Telemedicine | 2 | 2016 | 211 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2019 | 124 | 0.140 |
Why?
|
| Trust | 1 | 1998 | 25 | 0.140 |
Why?
|
| Computer Systems | 1 | 1998 | 9 | 0.140 |
Why?
|
| Case-Control Studies | 4 | 2014 | 739 | 0.140 |
Why?
|
| Quality Indicators, Health Care | 2 | 2011 | 52 | 0.140 |
Why?
|
| Physician's Role | 1 | 1998 | 29 | 0.140 |
Why?
|
| Biliary Tract Diseases | 2 | 2008 | 6 | 0.130 |
Why?
|
| Medical Staff, Hospital | 2 | 2018 | 22 | 0.130 |
Why?
|
| Urban Health | 1 | 1997 | 15 | 0.130 |
Why?
|
| Miniaturization | 2 | 2008 | 10 | 0.130 |
Why?
|
| Patient Discharge | 3 | 2007 | 109 | 0.130 |
Why?
|
| Integrated Advanced Information Management Systems | 1 | 1997 | 1 | 0.130 |
Why?
|
| Diabetic Ketoacidosis | 1 | 1997 | 6 | 0.130 |
Why?
|
| Chi-Square Distribution | 4 | 2010 | 145 | 0.130 |
Why?
|
| Hospitals, Veterans | 3 | 2007 | 22 | 0.130 |
Why?
|
| Hospitalization | 4 | 2020 | 201 | 0.130 |
Why?
|
| Colorectal Surgery | 1 | 2016 | 7 | 0.130 |
Why?
|
| Pathology, Clinical | 1 | 2016 | 11 | 0.130 |
Why?
|
| Treatment Refusal | 1 | 1996 | 8 | 0.130 |
Why?
|
| Barrett Esophagus | 2 | 2014 | 16 | 0.130 |
Why?
|
| Models, Econometric | 1 | 1996 | 5 | 0.120 |
Why?
|
| Primary Prevention | 1 | 1996 | 25 | 0.120 |
Why?
|
| Documentation | 2 | 2000 | 28 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 843 | 0.120 |
Why?
|
| Health Information Exchange | 1 | 2016 | 6 | 0.120 |
Why?
|
| Remote Sensing Technology | 1 | 2016 | 12 | 0.120 |
Why?
|
| Cell Phone | 1 | 2016 | 20 | 0.120 |
Why?
|
| Prognosis | 4 | 2014 | 811 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 433 | 0.120 |
Why?
|
| Outpatients | 3 | 2007 | 44 | 0.120 |
Why?
|
| Urban Population | 3 | 2003 | 95 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1997 | 125 | 0.110 |
Why?
|
| Total Quality Management | 2 | 2008 | 11 | 0.110 |
Why?
|
| Attitude of Health Personnel | 2 | 1997 | 150 | 0.110 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 485 | 0.110 |
Why?
|
| Butylscopolammonium Bromide | 1 | 2014 | 2 | 0.110 |
Why?
|
| Choice Behavior | 1 | 2015 | 28 | 0.110 |
Why?
|
| Gastrointestinal Agents | 2 | 2018 | 16 | 0.110 |
Why?
|
| Social Media | 1 | 2016 | 67 | 0.110 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2007 | 64 | 0.110 |
Why?
|
| Diffusion of Innovation | 2 | 2006 | 10 | 0.100 |
Why?
|
| Health Services Research | 2 | 2007 | 44 | 0.100 |
Why?
|
| Medical Informatics Computing | 1 | 2013 | 1 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2009 | 303 | 0.100 |
Why?
|
| Information Management | 1 | 2013 | 3 | 0.100 |
Why?
|
| Regression Analysis | 5 | 2004 | 211 | 0.100 |
Why?
|
| Occult Blood | 1 | 1993 | 5 | 0.100 |
Why?
|
| Preventive Health Services | 1 | 1993 | 16 | 0.100 |
Why?
|
| Hospital Information Systems | 1 | 1993 | 2 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 1995 | 186 | 0.100 |
Why?
|
| Ablation Techniques | 1 | 2012 | 13 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2006 | 996 | 0.100 |
Why?
|
| Osteoporosis | 2 | 2009 | 63 | 0.100 |
Why?
|
| Sigmoidoscopy | 1 | 1992 | 5 | 0.100 |
Why?
|
| Ambulatory Care | 2 | 2009 | 60 | 0.100 |
Why?
|
| Diuretics | 2 | 2003 | 13 | 0.090 |
Why?
|
| Odds Ratio | 3 | 1998 | 237 | 0.090 |
Why?
|
| Ligation | 2 | 2009 | 39 | 0.090 |
Why?
|
| Mammography | 1 | 1993 | 82 | 0.090 |
Why?
|
| Laser Coagulation | 2 | 2009 | 13 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1995 | 304 | 0.090 |
Why?
|
| Esophagus | 1 | 2012 | 72 | 0.090 |
Why?
|
| Health Services for the Aged | 1 | 1992 | 13 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 285 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2012 | 117 | 0.090 |
Why?
|
| Colonoscopes | 1 | 2011 | 1 | 0.090 |
Why?
|
| Self Care | 2 | 2003 | 42 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 415 | 0.090 |
Why?
|
| Societies, Medical | 2 | 2008 | 93 | 0.090 |
Why?
|
| Fluorescence | 1 | 2011 | 51 | 0.090 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2008 | 6 | 0.090 |
Why?
|
| Computers | 1 | 2011 | 30 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 1998 | 302 | 0.080 |
Why?
|
| Nurses | 1 | 2011 | 13 | 0.080 |
Why?
|
| Ink | 1 | 2010 | 3 | 0.080 |
Why?
|
| Indocyanine Green | 1 | 2010 | 16 | 0.080 |
Why?
|
| Photochemotherapy | 2 | 2012 | 42 | 0.080 |
Why?
|
| Ambulatory Care Facilities | 2 | 2002 | 54 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2007 | 288 | 0.080 |
Why?
|
| Pain Clinics | 1 | 2010 | 2 | 0.080 |
Why?
|
| Program Evaluation | 2 | 2009 | 174 | 0.080 |
Why?
|
| Equipment Failure | 1 | 2010 | 31 | 0.080 |
Why?
|
| Cachexia | 1 | 2011 | 53 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 54 | 0.080 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 32 | 0.080 |
Why?
|
| Cross Infection | 1 | 2010 | 37 | 0.080 |
Why?
|
| Hemoglobins | 1 | 2010 | 118 | 0.080 |
Why?
|
| Gastritis, Atrophic | 1 | 2009 | 2 | 0.080 |
Why?
|
| Deficiency Diseases | 1 | 2009 | 6 | 0.080 |
Why?
|
| Carbon | 1 | 2010 | 107 | 0.080 |
Why?
|
| Software | 1 | 2011 | 127 | 0.080 |
Why?
|
| Long-Term Care | 1 | 2009 | 32 | 0.080 |
Why?
|
| Acute Disease | 2 | 2007 | 155 | 0.080 |
Why?
|
| Prevalence | 2 | 2005 | 518 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2009 | 25 | 0.080 |
Why?
|
| Enema | 1 | 2009 | 7 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 58 | 0.080 |
Why?
|
| Lasers, Gas | 1 | 2009 | 1 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 536 | 0.080 |
Why?
|
| Electrocoagulation | 1 | 2009 | 20 | 0.080 |
Why?
|
| Syringes | 1 | 2009 | 8 | 0.080 |
Why?
|
| Prosthesis Design | 2 | 2006 | 88 | 0.080 |
Why?
|
| Device Removal | 1 | 2009 | 30 | 0.070 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2009 | 5 | 0.070 |
Why?
|
| Obesity | 1 | 1995 | 701 | 0.070 |
Why?
|
| Pleural Effusion | 1 | 2009 | 14 | 0.070 |
Why?
|
| Hemostatics | 1 | 2009 | 19 | 0.070 |
Why?
|
| Chest Tubes | 1 | 2009 | 9 | 0.070 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 30 | 0.070 |
Why?
|
| Parenteral Nutrition | 1 | 2009 | 8 | 0.070 |
Why?
|
| Cough | 1 | 2009 | 11 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 466 | 0.070 |
Why?
|
| Dyspnea | 1 | 2009 | 25 | 0.070 |
Why?
|
| Chest Pain | 1 | 2009 | 26 | 0.070 |
Why?
|
| Dissection | 1 | 2008 | 20 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 43 | 0.070 |
Why?
|
| Calcium | 1 | 2009 | 243 | 0.070 |
Why?
|
| Fiber Optic Technology | 1 | 2008 | 14 | 0.070 |
Why?
|
| Forms and Records Control | 1 | 2008 | 5 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 303 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 612 | 0.070 |
Why?
|
| Sclerosing Solutions | 1 | 2007 | 1 | 0.070 |
Why?
|
| Sclerotherapy | 1 | 2007 | 1 | 0.070 |
Why?
|
| Nutritional Status | 2 | 2000 | 80 | 0.070 |
Why?
|
| Coloring Agents | 1 | 2007 | 37 | 0.070 |
Why?
|
| Lithotripsy, Laser | 1 | 2007 | 1 | 0.070 |
Why?
|
| Sample Size | 1 | 2007 | 17 | 0.070 |
Why?
|
| Lithotripsy | 1 | 2007 | 9 | 0.070 |
Why?
|
| Disease Progression | 2 | 2007 | 479 | 0.070 |
Why?
|
| Cholelithiasis | 1 | 2007 | 10 | 0.070 |
Why?
|
| Hypertension | 1 | 1990 | 309 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2007 | 33 | 0.060 |
Why?
|
| Clinical Competence | 3 | 2018 | 239 | 0.060 |
Why?
|
| Gastrostomy | 2 | 2011 | 8 | 0.060 |
Why?
|
| Hyponatremia | 1 | 1986 | 17 | 0.060 |
Why?
|
| Tomography, Spiral Computed | 1 | 2006 | 8 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 226 | 0.060 |
Why?
|
| Dihematoporphyrin Ether | 1 | 2006 | 1 | 0.060 |
Why?
|
| Models, Organizational | 1 | 2006 | 18 | 0.060 |
Why?
|
| Stomach Diseases | 1 | 2006 | 4 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 22 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2006 | 118 | 0.060 |
Why?
|
| Anti-HIV Agents | 1 | 2006 | 20 | 0.060 |
Why?
|
| Esophageal Stenosis | 1 | 2006 | 3 | 0.060 |
Why?
|
| Duodenal Diseases | 1 | 2006 | 7 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 24 | 0.060 |
Why?
|
| Digestive System Neoplasms | 1 | 2006 | 5 | 0.060 |
Why?
|
| Esophageal Diseases | 1 | 2006 | 13 | 0.060 |
Why?
|
| Systems Analysis | 1 | 2006 | 2 | 0.060 |
Why?
|
| Deglutition Disorders | 1 | 2006 | 24 | 0.060 |
Why?
|
| Survival Rate | 2 | 2005 | 432 | 0.060 |
Why?
|
| Photosensitizing Agents | 1 | 2006 | 35 | 0.060 |
Why?
|
| Disposable Equipment | 1 | 2005 | 1 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1990 | 344 | 0.060 |
Why?
|
| Patient-Centered Care | 1 | 2006 | 38 | 0.060 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2005 | 4 | 0.060 |
Why?
|
| Myocardial Revascularization | 1 | 2005 | 14 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 379 | 0.060 |
Why?
|
| Jaundice, Obstructive | 1 | 2004 | 3 | 0.060 |
Why?
|
| Body Weight | 1 | 2006 | 250 | 0.060 |
Why?
|
| Hyperthyroidism | 1 | 2004 | 10 | 0.060 |
Why?
|
| Contrast Media | 1 | 2005 | 96 | 0.060 |
Why?
|
| Iodine Radioisotopes | 1 | 2004 | 36 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2005 | 76 | 0.060 |
Why?
|
| Health Services Needs and Demand | 1 | 2004 | 39 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2006 | 261 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 190 | 0.050 |
Why?
|
| Washington | 1 | 2004 | 13 | 0.050 |
Why?
|
| Patient Readmission | 1 | 2005 | 108 | 0.050 |
Why?
|
| Nonlinear Dynamics | 1 | 2003 | 17 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2003 | 20 | 0.050 |
Why?
|
| Personality Assessment | 1 | 2003 | 7 | 0.050 |
Why?
|
| Sick Role | 1 | 2003 | 9 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 2003 | 106 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2003 | 67 | 0.050 |
Why?
|
| Life Change Events | 1 | 2003 | 33 | 0.050 |
Why?
|
| Data Collection | 2 | 1996 | 106 | 0.050 |
Why?
|
| Congresses as Topic | 1 | 2003 | 35 | 0.050 |
Why?
|
| Low Back Pain | 1 | 2003 | 29 | 0.050 |
Why?
|
| Radiography | 2 | 2000 | 203 | 0.050 |
Why?
|
| Psychometrics | 1 | 2003 | 122 | 0.050 |
Why?
|
| Sickness Impact Profile | 1 | 2002 | 4 | 0.050 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2002 | 4 | 0.050 |
Why?
|
| Emergencies | 1 | 2002 | 28 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 2004 | 191 | 0.050 |
Why?
|
| Furosemide | 1 | 2001 | 7 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 429 | 0.040 |
Why?
|
| Comorbidity | 3 | 2001 | 261 | 0.040 |
Why?
|
| Interviews as Topic | 3 | 1998 | 162 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2001 | 73 | 0.040 |
Why?
|
| Osteoarthritis | 2 | 1993 | 39 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2004 | 916 | 0.040 |
Why?
|
| Infant | 2 | 2004 | 1026 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2004 | 1174 | 0.040 |
Why?
|
| North America | 1 | 2020 | 41 | 0.040 |
Why?
|
| Leiomyoma | 1 | 1980 | 9 | 0.040 |
Why?
|
| Heart Neoplasms | 1 | 1980 | 17 | 0.040 |
Why?
|
| Helicobacter pylori | 1 | 2000 | 18 | 0.040 |
Why?
|
| Helicobacter Infections | 1 | 2000 | 17 | 0.040 |
Why?
|
| Peptic Ulcer | 1 | 2000 | 11 | 0.040 |
Why?
|
| Research Design | 1 | 2001 | 187 | 0.040 |
Why?
|
| Uterine Neoplasms | 1 | 1980 | 80 | 0.040 |
Why?
|
| Telephone | 3 | 1999 | 26 | 0.040 |
Why?
|
| Communication Barriers | 1 | 1999 | 17 | 0.040 |
Why?
|
| Complementary Therapies | 1 | 1999 | 14 | 0.040 |
Why?
|
| Animals | 2 | 2010 | 10709 | 0.040 |
Why?
|
| Arthritis | 1 | 1999 | 29 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2000 | 243 | 0.040 |
Why?
|
| Insulinoma | 1 | 1999 | 2 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 1999 | 3 | 0.040 |
Why?
|
| Gastrinoma | 1 | 1999 | 3 | 0.040 |
Why?
|
| Death | 1 | 1998 | 8 | 0.040 |
Why?
|
| Geriatric Assessment | 2 | 2000 | 91 | 0.040 |
Why?
|
| Educational Status | 2 | 1999 | 112 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2000 | 156 | 0.040 |
Why?
|
| Health Surveys | 1 | 1998 | 85 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 203 | 0.040 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2018 | 3 | 0.040 |
Why?
|
| Glucagon | 1 | 2018 | 11 | 0.040 |
Why?
|
| Comprehension | 1 | 1998 | 20 | 0.040 |
Why?
|
| Nursing Homes | 1 | 1998 | 51 | 0.040 |
Why?
|
| Office Visits | 1 | 1998 | 8 | 0.030 |
Why?
|
| Operative Time | 1 | 2018 | 41 | 0.030 |
Why?
|
| Focus Groups | 1 | 1998 | 102 | 0.030 |
Why?
|
| Child | 2 | 2004 | 2292 | 0.030 |
Why?
|
| Advance Care Planning | 1 | 1998 | 15 | 0.030 |
Why?
|
| Life Expectancy | 1 | 1997 | 23 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2001 | 381 | 0.030 |
Why?
|
| Cardiac Catheterization | 1 | 1997 | 114 | 0.030 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1997 | 52 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 1997 | 20 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 1997 | 11 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 1997 | 68 | 0.030 |
Why?
|
| Episode of Care | 1 | 1997 | 4 | 0.030 |
Why?
|
| Qualitative Research | 1 | 1998 | 205 | 0.030 |
Why?
|
| Emotions | 1 | 1998 | 138 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 1996 | 46 | 0.030 |
Why?
|
| Psychological Tests | 1 | 1996 | 21 | 0.030 |
Why?
|
| Communication | 1 | 1998 | 182 | 0.030 |
Why?
|
| Esophagoscopy | 1 | 2014 | 16 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2014 | 62 | 0.030 |
Why?
|
| Education, Medical, Continuing | 2 | 2012 | 34 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 1995 | 58 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 257 | 0.030 |
Why?
|
| Computer Security | 1 | 2013 | 3 | 0.030 |
Why?
|
| Software Design | 1 | 2013 | 7 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 247 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 465 | 0.030 |
Why?
|
| Fees and Charges | 1 | 1993 | 1 | 0.020 |
Why?
|
| Hospital Bed Capacity, 300 to 499 | 1 | 1993 | 2 | 0.020 |
Why?
|
| Microcomputers | 1 | 1993 | 4 | 0.020 |
Why?
|
| Computer Communication Networks | 1 | 1993 | 4 | 0.020 |
Why?
|
| Time and Motion Studies | 1 | 1993 | 7 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2014 | 515 | 0.020 |
Why?
|
| Argon Plasma Coagulation | 1 | 2012 | 1 | 0.020 |
Why?
|
| Cryotherapy | 1 | 2012 | 10 | 0.020 |
Why?
|
| Patient Care | 1 | 2012 | 13 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 266 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 1990 | 391 | 0.020 |
Why?
|
| Faculty, Medical | 1 | 2012 | 59 | 0.020 |
Why?
|
| Drug Utilization | 1 | 1992 | 28 | 0.020 |
Why?
|
| Psychotherapy | 1 | 1992 | 16 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 1992 | 29 | 0.020 |
Why?
|
| Equipment Reuse | 1 | 2010 | 3 | 0.020 |
Why?
|
| Disinfectants | 1 | 2010 | 14 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 2 | 2001 | 58 | 0.020 |
Why?
|
| Medical Device Recalls | 1 | 2010 | 1 | 0.020 |
Why?
|
| Compassionate Use Trials | 1 | 2010 | 1 | 0.020 |
Why?
|
| Hepatitis C Antibodies | 1 | 2010 | 7 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 202 | 0.020 |
Why?
|
| Off-Label Use | 1 | 2010 | 6 | 0.020 |
Why?
|
| Ribavirin | 1 | 2010 | 9 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2012 | 223 | 0.020 |
Why?
|
| Social Support | 1 | 1991 | 129 | 0.020 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2010 | 13 | 0.020 |
Why?
|
| Viral Load | 1 | 2010 | 32 | 0.020 |
Why?
|
| Ibuprofen | 1 | 1990 | 17 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2010 | 49 | 0.020 |
Why?
|
| Creatinine | 1 | 1990 | 59 | 0.020 |
Why?
|
| Interferons | 1 | 2010 | 70 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 68 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 1990 | 61 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2010 | 114 | 0.020 |
Why?
|
| Blood Pressure | 1 | 1990 | 357 | 0.020 |
Why?
|
| Safety | 1 | 2007 | 32 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 48 | 0.020 |
Why?
|
| Injections | 1 | 2007 | 31 | 0.020 |
Why?
|
| Pancreatic Ducts | 1 | 2007 | 10 | 0.020 |
Why?
|
| Liver | 1 | 2010 | 471 | 0.020 |
Why?
|
| Oklahoma | 1 | 2010 | 1055 | 0.020 |
Why?
|
| Risk | 1 | 1986 | 138 | 0.020 |
Why?
|
| Statistics as Topic | 2 | 1999 | 79 | 0.010 |
Why?
|
| Hospital Charges | 1 | 2004 | 8 | 0.010 |
Why?
|
| Bilirubin | 1 | 2004 | 11 | 0.010 |
Why?
|
| Reading | 1 | 1985 | 19 | 0.010 |
Why?
|
| Preventive Medicine | 1 | 1985 | 14 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 73 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2004 | 78 | 0.010 |
Why?
|
| Accidents, Traffic | 1 | 2004 | 28 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2004 | 51 | 0.010 |
Why?
|
| Violence | 1 | 2004 | 31 | 0.010 |
Why?
|
| Accidental Falls | 1 | 2004 | 34 | 0.010 |
Why?
|
| Self Efficacy | 1 | 2003 | 80 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 150 | 0.010 |
Why?
|
| Radionuclide Ventriculography | 1 | 2001 | 1 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 2001 | 16 | 0.010 |
Why?
|
| Biological Availability | 1 | 2001 | 44 | 0.010 |
Why?
|
| Echocardiography | 1 | 2001 | 110 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2001 | 238 | 0.010 |
Why?
|
| Morbidity | 1 | 2000 | 60 | 0.010 |
Why?
|
| Models, Economic | 1 | 2000 | 8 | 0.010 |
Why?
|
| Arthralgia | 1 | 1999 | 7 | 0.010 |
Why?
|
| Heart Atria | 1 | 1980 | 177 | 0.010 |
Why?
|
| Angiography | 1 | 1999 | 35 | 0.010 |
Why?
|
| Selection Bias | 1 | 1997 | 13 | 0.010 |
Why?
|
| Palliative Care | 1 | 1993 | 86 | 0.010 |
Why?
|
| Morale | 1 | 1991 | 1 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1991 | 66 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 1990 | 19 | 0.010 |
Why?
|
| Acetaminophen | 1 | 1990 | 11 | 0.010 |
Why?
|
| Consumer Behavior | 1 | 1989 | 14 | 0.000 |
Why?
|
| Disability Evaluation | 1 | 1989 | 54 | 0.000 |
Why?
|
| Acute Kidney Injury | 1 | 1990 | 74 | 0.000 |
Why?
|
| Pain | 1 | 1989 | 258 | 0.000 |
Why?
|
| Random Allocation | 1 | 1985 | 151 | 0.000 |
Why?
|